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Abstract  
Background 
HOX genes are a family of developmental genes that are neither expressed in the 
developing forebrain nor in normal brain. Aberrant expression of a HOX-gene 
dominated stem-cell signature in glioblastoma has been linked with increased 
resistance to chemo-radiotherapy and sustained proliferation of glioma initiating cells. 
Here we describe the epigenetic and genetic alterations and their interactions 
associated with the expression of this signature in glioblastoma.  
Results 
We observe prominent hypermethylation of the HOXA locus 7p15.2 in glioblastoma 
in contrast to non-tumoral brain. Hypermethylation is associated with a gain of 
chromosome 7, a hallmark of glioblastoma, and may compensate for tumor-driven 
enhanced gene dosage as a rescue mechanism by 
preventing undue gene expression. We identify the CpG island of the HOXA10 
alternative promoter that appears to escape hypermethylation in the HOX-high 
glioblastoma. An additive effect of gene copy gain at 7p15.2 and DNA methylation at 
key regulatory CpGs in HOXA10 is significantly associated with HOX-signature 
expression. Additionally, we show concordance between methylation status and 
presence of active or inactive chromatin marks in glioblastoma-derived spheres that 
are HOX-high or HOX-low, respectively. 
Conclusions 
Based on these findings, we propose co-evolution and interaction between gene copy 
gain, associated with chromosome 7 gain, and additional epigenetic alterations as key 
 - 5 - 
mechanisms triggering a coordinated, but inappropriate, HOX transcriptional program 
in glioblastoma.  
Keywords 
glioblastoma; epigenomics; DNA methylation; trisomy 7; gene expression; HOX 
genes; TCGA 
  
 - 6 - 
Background  
Glioblastoma (GBM) is an aggressive brain tumor with a median survival of only 15 
months. Despite remarkable efforts targeting prominent pathogenetic biological 
features of GBM, efficacy of novel drugs has been disappointing and significant gains 
in overall survival have not been made since the introduction of combined radio-
chemotherapy comprising TMZ [1]. GBM are notorious for their treatment resistance. 
This has been attributed to the deregulation of major tumor suppressing and 
oncogenic pathways [2], tumor heterogeneity [3], and exhibition of stem cell-like 
properties by so called tumor stem cells, or glioma initiating cells (GICs) [4]. GICs 
represent a subpopulation(s) of tumor cells and are believed to firstly give rise to 
tumor progeny due to their self-renewing capacities, and secondly, resist radio- and 
chemotherapy [5, 6].  
In line with the notion of GICs’ contribution to treatment resistance, we earlier 
reported a self-renewal-related, HOX dominated gene expression signature in GBM 
associated with significantly worse outcome in patients homogenously treated in a 
clinical trial with combined chemo-radiotherapy comprising the alkylating agent 
temozolomide. This association was independent of the predictive effect of MGMT 
methylation or age [7]. The abnormal expression of a HOX gene signature has been 
confirmed recently in GICs, where it has been functionally associated with their 
glioma initiating potential [8]. The importance of HOX gene expression for 
gliomagenesis and treatment resistance to temozolomide has been emphasized in 
several studies [8-12]. In 2006, Krivtsov and colleagues first described the 
inappropriate expression of a HOX gene signature in acute myeloid leukemia (AML) 
[13]. The authors showed in an elegant experimental mouse model that acquisition of 
this stem cell related HOX gene signature was associated with MLL-A9 fusion gene-
induced leukemogenesis from committed progenitors of the granulocyte lineage, 
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demonstrating for the first time that acquisition of stem cell properties in committed 
progenitor cells can lead to tumorigenesis.   
HOX genes are a highly conserved family of genes encoding homeodomain 
transcription factors that provide anterior and posterior axial coordinates to vertebrate 
embryos during development [14]. In mammals, there are four paralogous HOX gene 
clusters organized on different chromosomes (CHRs). These gene clusters represent 
loci with extremely high gene density. In humans they are located on CHR7 (HOXA), 
CHR17 (HOXB), CHR12 (HOXC), and CHR2 (HOXD). The spatial organization of 
HOX genes is reflected in a 5'-posterior to 3'-anterior expression along the embryonal 
axes, termed spatial colinearity. Hence, expression of HOXA9-13 is predominantly 
found in sites of the extremities, while HOXA1-2 expression has been confirmed in 
e.g. the hindbrain. Although HOX genes are involved in the development of the 
hindbrain, other non-HOX homeobox genes regulate the development of the mid- and 
forebrain [15]. The forebrain comprises the ventricular and the subventricular zone, 
which harbours neural stem cells even in the adult brain, and has been proposed as 
origin of gliomas in the adult. Although this remains debated, mouse models have 
provided functional support [16].  
Given that HOX genes are neither implicated in the developmental program of the 
brain nor expressed in the region of the adult brain that is thought to give rise to 
gliomas, we speculate that the HOX-signature is acquired during gliomagenesis, 
contributing stem cell properties. However, the mechanisms underlying the observed 
aberrant activation of HOX genes in GBM remain elusive. It has been proposed that 
the PI3K-pathway may be an important upstream regulator of HOXA9 expression that 
is part of the HOX-signature [10]. A more recent report considered the involvement of 
MLL (KMT2A) in at least a subset of HOX-high expressing GBM. However, given 
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the limited correlation reported, additional driver mechanisms triggering inappropriate 
HOX gene expression need to be considered [8]. Previous works have described a 
remarkable correlation of gene expression levels with gene dosage modulated by 
pathogenic copy number changes in cancer [17]. Most prominent among the HOX 
expression signature genes are HOXA genes, as corroborated by other labs [7, 8, 10]. 
The HOXA locus is located on CHR7 (7p15.2) that is affected by a copy number gain 
in up to 80% of GBM [18]. Most interestingly, gain of CHR7 has been proposed 
recently as the evolutionary first driver event in the development of primary GBM 
together with loss of one copy of CHR10 [19]. CHR7 harbours a number of potential 
driver genes, among many passengers that through CHR7 gain associated 
overexpression may drive/contribute to gliomagenesis. Of these, Ozawa et al. 
proposed PDGF as a driver gene for primary GBM, based on computational and 
experimental considerations. Previously we reported a low, but significant correlation 
between gene copy number of the HOXA cluster and expression of the HOX-signature 
[7]. However, only 42% of this patient cohort was found to be HOX-high. We 
therefore hypothesized that additional regulatory mechanisms are required to explain 
the abnormal expression of HOXA genes, with down-stream effects on other HOX-
signature genes. Here we present a model explaining the aberrant expression of the 
HOX-signature in GBM integrating multidimensional molecular data, comprising 
gene expression, gene copy number, and DNA methylation. 
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Results  
Correlation between DNA methylation and gene expression in clinical GBM 
samples 
During gliomagenesis extensive epigenetic remodelling takes place, including global 
DNA hypomethylation and focused hypermethylation of promoter CpG-islands 
(CGIs) frequently silencing tumor suppressor genes. Recurrent gain of additional 
copies of CHR7 in GBM, often referred to as trisomy 7 in the literature, likely affects 
the HOXA locus that dominates the HOX-signature. The “HOX-signature” refers to 
the signature identified previously [7], and comprises 21 genes covered by 22 probes 
of the HG-133Plus2.0 GeneChip (Table S1). We hypothesized that epigenetic 
silencing mediated by methylation of CpGs in CGI-promoters of HOX-signature 
genes may compensate for tumor driven enhanced gene dosage as a rescue 
mechanism that could at least partially explain the differences in expression. In order 
to test this hypothesis we analysed DNA methylation profiles of 59 GBM of the 
NCH_EORTC cohort obtained on the Illumina Infinium HumanMethylation450 
BeadChip platform (450K). Indeed we found significant differences in the mean 
methylation across the HOXA locus on CHR7 (27,130,000 to 27,250,000; hg19 
UCSC), when comparing GBM to non-tumoral brain (n=4), with a generalized 
hypermethylation in the GBM samples as measured at 504 450k probes spanning the 
locus (p < 0.001, two-sided t-test; Figures S1 & S2). DNA methylation of the HOXA 
locus was significantly associated with gain of CHR7 (p < 0.001, two-sided t-test), 
which may indicate compensation for increased gene dosage. In order to identify 
regulatory methylation patterns relevant for the expression of the whole HOX-
signature the 400 probes annotated in CGIs of the 21 HOX-signature genes were 
subjected to principle component analysis. The top 100 CpG probes were selected 
based on their ranked cumulative contribution to the inertia of the DNA methylation 
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table, hence representing the dominant contributors to the overall variability of the 
observed DNA methylation. The top 100 probes were predominantly located in the 
promoter CGIs of HOXA genes on CHR7, followed by HOXD genes on CHR2, 
HOXC genes on CHR12, and PROMININ1 on CHR4 (Figure 1A and Table S2 in 
additional file 2, which contains mean correlation, p- and q-values, and functional 
annotation for all 100 selected Infinium 450k probes for NCH_EORTC and TCGA 
data). The correlation between methylation at these CpGs and expression of each 
member of the HOX-signature was calculated. The heatmap of the correlation matrix 
(Figure 1A) visualizes the pattern of negative and positive correlation between DNA 
methylation and gene expression in this GBM dataset. The strongest mean negative 
correlation (<=-0.28, [-0.28; 0.4]) between expression of HOX-signature genes and 
methylation was observed for a CpG probe located in the CGI associated with the 
alternative transcription start site of HOXA10 (probe ID cg05092861 in UCSC CpG 
Island CHR7: 27219309-27219750, FDR < 0.10) (Figure 1B, Table S2). An adjacent 
CpG showed a similar correlation (cg01078824; -0.21, FDR < 0.10; Table S2).  
 
Determination of the correlation signature in an independent GBM dataset 
Likewise we calculated the correlation matrix between DNA methylation and gene 
expression in an independent dataset of 106 GBM from The Cancer Genome Atlas 
(TCGA; Table S4; mean correlation Figure 1C) visualized in a heatmap in Figure S3 
The similarity of the structure of the correlation matrices was remarkable for these 
two independent GBM datasets, with a RV-coefficient of 0.84 (simulated p-value < 
0.001 [9999 permutations], Figures S3 & S4). Of note, while DNA methylation data 
was also generated on the 450k platform (used as the common dimension), the 
expression data originated from different platforms. In the GBM TCGA Agilent data 
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the HOX-signature genes are covered with 53 probes (Table S5), with probes missing 
for the ncRNA genes MIR10B and HOTAIRM1.  
 
In order to evaluate the relevance of our findings in the context of the whole CHR7, 
we tested whether the apparent local enrichment of negative correlation between 
HOXA gene expression and DNA methylation at the HOXA locus was statistically 
significant. We determined the negative correlations between 711 RefSeq annotated 
CHR7 genes and their respective Illumina Infinium 450k probes and plotted the 
values according to genomic location of the genes (Figure S5A). Gene set enrichment 
analysis (GSEA) revealed that the 10 HOXA genes were significantly enriched when 
testing their positions in the ranked list of the observed correlation coefficients of the 
711 CHR7 genes as visualized in Figure S5B (p-value < 0.001, Table S3). A similar 
result was obtained for the TCGA dataset (p-value < 0.001; Figure S5C; Table S3). 
 
The relationship DNA methylation/gene expression depends on CpG location 
Next we were interested to evaluate the relationship of the mean correlation 
methylation/HOX-signature expression (Figures 1B & C) and the structural location 
of the respective CpGs using the Illumina annotation of the 450k probes (1st Exon, 
3’UTR, 5’UTR, gene body, transcription start site (TSS) 1500, TSS200). We 
observed that negative correlations between DNA methylation and the HOX-signature 
expression are primarily found for probes which are located either in the 1st exon of a 
gene, or within 200bp of TSS, in line with canonical effects of promoter-CGI 
methylation on gene expression, while positive mean DNA methylation/gene 
expression correlations were found for probes located in the 3’UTR, 5’UTR, gene 
body and within 1500bp of TSS. This observation was consistent between the 
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NCH_EORTC and the TCGA dataset (Figure S6A & B, p value < 0.01 & p value < 
0.05, one-way ANOVA).  
 
DNA methylation at HOXA10 promoter CGI is lower in HOX-high than HOX-low 
GBM 
The 59 GBM (NCH_EORTC) were classified into HOX-high (N = 25) or low (N = 
34) based on iterative k-means clustering of the 22 Affymetrix probesets (Figures S7 
& S8). The average expression of the HOX-signature in the HOX-low group is not 
significantly different from respective measures in non-tumoral brain samples (p-
value = 0.9, all Welch’s Two-sample t-test) (Figure S9A). In contrast, the higher 
mean expression levels of the HOX-signature in HOX-high samples are significantly 
different to both HOX-low (p-value < 0.01) and non-tumoral brain samples (p-value < 
0.01). We observed significant differences in the degree of DNA methylation 
measured for probe cg05092861 between HOX-low and HOX-high samples, with a 
higher level of DNA methylation in HOX-low samples (p-value < 0.001). Both were 
different from non-tumoral brain (n = 4), which showed the lowest methylation levels 
(p-value < 0.001), although no expression is detected, while highest levels of DNA 
methylation were measured in HOX-low samples (non-tumoral brain < HOX-high < 
HOX-low, Figure S9B). Similar differences were observed for the adjacent Infinium 
450k probe cg01078824. 
 
Correlation between expression and gene copy number 
In order to investigate our hypothesis that gene dosage may contribute to the aberrant 
expression of the HOX-signature, we first tested the overall relationship between gene 
dosage and gene expression in our GBM dataset (NCH_EORTC). At the resolution of 
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chromosomal arms that averages out regulatory factors affecting individual transcript 
levels, expression of the genes located on that arm and corresponding DNA copy 
number are strongly correlated (median Pearson correlation coefficient 0.73, standard 
deviation 0.18). The gene dosage effect on expression is particularly striking for gain 
of CHR7 and loss of CHR10, both hallmarks of GBM, as visualized in Figure 2 for 
the whole NCH-EORTC cohort (Figure 2A and B), or individual GBM samples 
(Figure 2C and D).  
 
Gene dosage and DNA methylation impact HOX-signature expression  
Next we tested the association between copy number alterations (CNA) at cytoband 
7p15.2 that harbours the HOXA locus, methylation at the selected CpG (cg05098261) 
in the alternative promoter of HOXA10, and mean HOX-signature expression levels 
using an explanatory linear model. The M-values of the probe cg05092861 and the 
respective CNA values for cytoband 7p15.2 were introduced as independent variables, 
while the mean HOX-signature expression (based on scaled and centred gene 
expression) was the dependent variable. We observed a significant additive effect 
between CNA 7p15.2 and methylation at the selected probe in the alternative 
promoter of HOXA10 as illustrated in Figure 3A. This model explains 32% of the 
variance of the HOX-signature expression levels (Table 1 – “Model 1”). The result 
supports the hypothesis that DNA methylation – at least in part - acts as an attenuating 
factor in samples with increased CNA at 7p15.2 in a manner that the effect of 
increased gene dosage on expression may be countered by the inhibitory effect of 
DNA methylation of HOXA10 in GBM. Similar results were also observed in the 
TCGA subset of 103 GBM (for 3 of the 106 TCGA GBM the SNP6 CNA data was 
not available) as viusalized in Figure 3B and summarized in Table 1. The model for 
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the TCGA data explains 29% of the observed variance in HOX-signature expression 
(Table 1 – “Model 1”). Similar additive effects were observed for the adjacent CpG 
(cg01078824, Table 1 – “Model 2”).  
Given the apparent central role of HOXA10 in the HOX-signature, X/Y plots for both 
series of GBM, stratified by CHR7 status,  illustrate the correlation between HOXA10 
expression alone (Affymetrix probe 214651_s_at) and methylation at the above 
identified 2 top CpGs (cg05092861, cg01078824) in the promoter of the putative non-
coding alternative HOXA10 transcript (NR_037939.1) and in addition at 2 CpGs 
(cg18243072, TSS200; cg14625175, exon1) located in the CGI of the promoter of the 
canonical HOXA10 protein-coding transcript (NM_018951.3) (Figure 4B & C). In our 
dataset (NCH_EORTC) a significant negative correlation between expression and 
methylation was associated with CpG methylation in both regions for HOXA10 
expression in GBM with CHR7 gain (Spearman’s correlation p < 0.05, Figure 4B & 
C). In contrast, no significant correlation was observed in GBM with normal CHR7 
status (Figure 4B & 4C). Taken together, the findings for the HOX-signature gene 
HOXA10 are in accordance with the model presented in Figure 3. Similar results were 
obtained for the TCGA dataset (Figure S10B & C). The Spearman’s correlation 
coefficients for CpGs located in the two HOXA10 promoters and HOXA10 expression 
are available in Table S6 for both datasets, stratified by CHR7 status. Table S7 
comprises the correlation coefficients for the top 100 CpGs and  mean expression of 
the whole HOX-signature, stratified by CHR7 status for both NCH_EORTC and 
TCGA GBM.  
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Transcriptome at the HOXA locus in GBM derived sphere (GS) lines 
We sought to extend our findings to four GBM-derived sphere lines (GS-lines) that 
retain GBM-relevant stem-cell properties and provide a better model of GBM than 
regular cell lines. Aligned read pile-ups derived from directed RNA-Seq data shown 
in Figure 5 illustrate the presence of both sense and anti-sense transcripts in the 
HOXA locus in three GS-lines (LN-2207GS, LN-2669GS, LN-2683GS, thus 
designated as HOX-high models). In contrast, RNA-Seq reads generated from the 
HOX-low GS-line LN-2540GS and human brain tissue (Ensembl Illumina Human 
BodyMap 2.0) show only very few and no aligned reads across the HOXA locus, 
respectively. These data confirm that the expression of transcripts from the HOXA 
locus in HOX-high GS–lines is abnormal when compared to adult “normal” brain. In 
the three HOX-high GS-lines, the visualization of read alignments show that the 
majority of fragments originated from exons of HOXA10, with presence of some 
transcripts for HOXA9 exons. We then used the RNA-Seq data to perform reference 
annotation based transcript assembly using cufflinks. This mapped transcript 
fragments of the three HOX-high GS-lines to 12 of the 15 canonical HOXA sense and 
anti-sense transcripts. Additionally, using transcriptome re-assembly we found that 
the mapping of some of the transcript fragments suggests that a read-through 
transcript may be present, possibly consisting of exons of HOXA10, miR-196b, 
HOXA9 and the putative protein-coding RNA RP1-170O19.20. The presence of the 
AFFY-probes 214651_s_at and 209905_at in the HOX-signature that have been 
annotated as long non-coding RNA gene HOXA10-HOXA9 lend some support to 
these findings. A model of this putative read-through transcript, based on the cufflinks 
reconstruction of the transcriptome of the GS-lines, is visualized in the HOXA locus 
Figure 5. A Sashimi plot of the HOXA10-9 locus (Figure S12) illustrates the presence 
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of transcript fragments, which span the exon/exon junctions of HOXA9, HOXA10, 
miR-196b and RP1-170O19.20. However, further studies are warranted. 
 
Histone marks and promoter methylation at the HOXA10/9 promoters 
One important regulatory mechanism of transcription is the conformational state of 
chromatin, as mediated through various post-translational histone modifications. The 
observation that HOXA genes are actively transcribed in a subset of GBM and in three 
of our four GS-lines indicates that the chromatin is in a permissive state. We tested 
this assumption by performing chromatin-immunoprecipitation (ChIP) in the four GS-
lines for three different histone marks, H3K4me3 – mark for active or poised 
promoters, H3K36me3 – indicative of transcriptional elongation, and H3K27me3 – a 
repressive mark, followed by qPCR at the promoters of HOXA10 and HOXA9, (Figure 
6A & B). ChIP-qPCR revealed a predominant signal for H3K4me3 and presence of 
H3K36me3 in the HOX-high GS-lines (LN-2207GS, LN-2669GS, LN-2683GS) in 
the HOXA10 promoter, while they were absent in the HOX-low GS-line LN-2540GS. 
In contrast, the predominant mark detected in the HOXA9 promoter was H3K36me3, 
while the other marks were absent. In addition, we determined the methylation status 
using methylation-specific (MS) clone sequencing of the CpG island of the HOXA10 
promoter (CHR7:27212417-27214396) in three GS-lines (2 HOX-high and 1 HOX-
low) and their respective original GBM. The methylation pattern in the GS-lines was 
highly similar to the original primary tumors from which they were isolated, 
excluding an in vitro artefact (Figure 6C & D). The HOXA10 promoter was 
unmethylated in the two HOX-high GS-lines LN-2207GS and LN-2669GS and their 
respective original GBM, and fully methylated in the HOX-low GS line LN-2540GS 
and the respective GBM-2540. This corroborates our finding of strong negative 
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correlations between expression/methylation for 2 CpGs (cg18243072, cg14625175) 
interrogated in this region on the 450k BeadChip, as illustrated and annotated in X-Y-
plots for both NCH_EORTC (Figure 4) and TCGA samples (Figure S10). MS clone 
sequencing of the HOXA9 promoter (CHR7:27205048-27205315) revealed full 
methylation also in the HOX-high GS-lines (Figure 6E). Taken together, the marks 
for actively transcribed chromatin are in accordance with HOXA10 expression. 
HOXA10 is also translated into protein as we have published previously for GS-lines, 
including LN-2207GS and a series of GBM on a tissue micro array [7]. The observed 
enrichment for the elongation mark H3K36me3 at the fully methylated HOXA9 
promoter would be compatible with the presence of a putative read-through transcript 
of HOXA10 and HOXA9, as suggested by our analyses of the RNA-Seq data (Figures 
5 & S12) and the probe annotation from the HG-133Plus2.0 GeneChip.  
 
HOX-signature associated microRNAs 
To test for the potential impact of regulatory microRNAs on the HOX-signature we 
analysed the correlation between the mean expression of the HOX-signature in the 
TCGA Agilent data subset and the expression levels of individual microRNAs (Table 
2). We found that the top correlated microRNAs (Spearman’s rho >= 0.5, p value < 
0.0001) were in fact transcribed from HOX loci (miR-196b – HOXA, miR-10a – 
HOXB, miR-10b – HOXD), known to have regulatory functions in cis [20]. However, 
the expression of these microRNAs was positively correlated, suggesting that the de-
repression of HOX genes in GBM may lead to an overall aberrant co-expression of 
genes from the affected loci including the enclosed microRNAs. This is further 
supported by the observation that several long non-coding RNAs transcribed from the 
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HOXA (HOTAIRM1) and HOXC loci (LOC400043, HOTAIR) and adjacent to the 
HOXD locus (LOC375295), were detected as part of the HOX-signature (Table S1). 
 
Relationship of the HOX-signature and molecular GBM subtypes  
Next we sought to address how the HOX-signature was related to three established 
molecular GBM classification schemes: i) the four GBM expression subtypes neural, 
proneural, mesenchymal and classical as proposed by Verhaak and colleagues [21], ii) 
the glioma CpG island methylator phenotype (G-CIMP) present in a subgroup of 
proneural GBM [22], iii) or distinction of MGMT promoter methylated vs 
unmethylated that has been shown to be highly predictive for benefit from alkylating 
agent chemotherapy [23]. Expression data from 473 GBM (TCGA, level 2 Agilent) 
were used to classify samples into either HOX-high (259) or low (214), based on k-
means clustering (Figure S13), and were annotated with the expression subtype 
classification, including G-CIMP, and MGMT promoter methylation status [2, 24] 
(Figure S14). We observed an enrichment of proneural GBM in the HOX-high group, 
while the proneural G-CIMP-positive GBM were underrepresented (Table S8, p-value 
<0.001, Pearson’s Chi-squared test). No significant associations were found in the 
other three expression subtypes. No correlation was found with expression of PDGF 
that has been proposed as a gain of CHR7-associated driver gene for G-CIMP 
negative GBM [19]. Finally, we confirmed our previous finding from the 
NCH_EORTC dataset [7] that the MGMT-promoter methylation frequency was not 
different between the HOX-high and low groups (Table S9, p-value > 0.35, Pearson’s 
Chi-Squared test). 
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Discussion  
In the present study we sought to elucidate underlying molecular mechanisms 
triggering the inappropriate expression of a HOX-signature. Such HOX gene 
dominated expression signatures have been associated by us and others with 
resistance to temozolomide and conferring glioma-initiating properties [7, 8, 11, 12].  
The hypermethylation of the HOXA locus was associated with gain of CHR7, which is 
reminiscent of compensation for increased gene dosage, known from X-chromosome 
inactivation [25-28]. This is further supported by the observation that a significant 
correlation between DNA methylation and expression was only observed for samples 
with gain of CHR7 as visualized for HOXA10. The involvement of gene dosage 
mediated induction of HOX-signature expression is compatible with the observation 
that HOX-high GBM are underrepresented in G-CIMP positive GBM, which 
reportedly have a much lower frequency of CHR7 gain [2]. The observed correlation 
between expression of the whole HOX-signature and DNA methylation suggested 
DNA methylation patterns permissive for expression. However, the regulatory effects 
leading to coordinated expression of HOXA, C and D genes, and the other members of 
the signature, including the stem cell marker PROM1 that are located on other 
chromosomes, are not yet explained. With the exception of the developing forebrain 
where HOX genes are repressed [29], the coordinated expression and silencing of 
HOX genes is well known from embryonic development. It involves changes of 
higher chromatin organization and complex regulation implicating long-range control 
mechanisms which are only partly understood [14]. 
HOX genes are tightly regulated through polycomb-repressor complex 2 (PRC2)-
mediated tri-methylation of H3K27 [30]. Investigation of GS-lines suggested loss of 
the repressive mark H3K27me3 and gain of the active mark H3K4me3 in the 
promoter of HOXA10 protein-coding transcript variant 1 in HOX-high GS-lines, and 
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was associated with an unmethylated CGI. This observation is in accordance with the 
detection of HOXA10 protein in HOX-high GS-lines, as well as in a subset of GBM 
[7]. In contrast, the HOX-low GS-line lacked the active mark and displayed a 
methylated HOXA10 promoter. Interestingly, the histone marks in the HOXA9 
promoter displaying enrichment of H3K36me3 in the HOX-high GS-lines in 
conjunction with the fully methylated CGI suggested transcriptional elongation. This 
pattern of histone marks would also be compatible with presence of a HOXA10/9 
read-through transcript, as proposed by the RNA-Seq analysis and the respectively 
annotated HG-133Plus2.0 probes that are part of the HOX-signature. Little is known 
about the functional relevance of the putative long non-coding RNA gene HOXA10-
HOXA9. It has been proposed as candidate for nonsense-mediated mRNA decay 
(NMD) [31-33]. 
Non-coding RNAs, like lincRNAs and microRNAs, can be involved in the regulation 
of HOX gene expression [34-36]. Our HOX-signature also includes several lincRNAs, 
which are transcribed from the different HOX loci: LOC400043 and HOTAIR from 
the HOXC locus, HOTAIRM1 from the HOXA locus, and LOC375295 from the 
HOXD locus. For the lincRNAs HOTAIR and HOTAIRM1 functions have been 
investigated. HOTAIRM1 can regulate the expression of HOXA genes through 
facilitating conformational changes to the chromatin, in proximal distal manner [35-
38]. An initial suspicion that HOTAIRM1 and other ncRNAs could be directly 
involved in the regulation of the HOX-signature genes was tantalizing. However, their 
expression pattern, taken together with the observation that top three microRNAs are 
actually transcribed from the HOXA/B/C/D loci, rather suggested that these small and 
long non-coding RNAs are more likely “caught in the storm” of aberrant transcription 
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from their respective HOX loci as part of a coordinated, but inappropriate 
transcriptional program. 
Conclusions  
In conclusion, our results suggest that the inappropriate expression of the HOX-
signature, which confers stem cell related properties and resistance to therapy, may be 
acquired through gene copy gain associated with CHR7 gain. Hypermethylation 
appears to compensate for gene copy gain at this locus in the HOX-low GBM, 
preventing CHR7 gain driven increase of expression, while in HOX-high GBM key 
CpGs in the HOXA locus escape hypermethylation. Gene copy gain and methylation 
at key CpGs in the promoter of HOXA10 putative non-coding transcript variant 2 are 
strongly associated with the expression of the whole HOX-signature. These findings 
are remarkably reproducible in an independent GBM dataset from TCGA. The 
observed mechanism of escape from DNA hypermethylation may explain 
overexpression of other gliomagenesis relevant proto-oncogenes located on CHR7 
and other loci affected by tumor related increased gene dosage. Hence, further studies 
are warranted to investigate the co-evolution of gene copy number changes and 
epigenetic changes, including tumorigenesis-associated DNA methylation, to identify 
tumor relevant deregulated genes. Finally, the observation of compensatory DNA 
methylation at genes with potential proto-oncogenic function should be taken into 
account when considering epigenetic drugs.  
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Methods 
GBM data sets and GBM derived sphere lines 
Our patient cohort of 59 GBM patients (NCH_EORTC), for which Affymetrix HG-
133Plus2.0 gene expression and Illumina Infinium 450k DNA methylation data were 
available, has been treated within clinical trials [39, 40]. Patients treated within 
EORTC 26981 had consented for translational research of their tumor tissues as part 
of the study protocol. All other patients gave informed consent according to the 
protocol approved by the local ethics committee (protocol F25/99) and the 
respective competent Swiss federal authorities (No 1.05.01.10-48). The study 
protocols conform with the World Medical Association Declaration of Helsinki [41]. 
Analysis of non-tumoral brain samples and the establishment of the GBM derived 
sphere lines (GS lines) LN-2207GS, LN-2540GS, LN-2669GS, and LN-2683GS, 
respective authentication, and the description of the respective original tumors have 
been published previously [7, 42, 43]. Briefly, GS lines were cultured under stem cell 
conditions using DMEM-F12 medium (Invitrogen, 10565-018) supplemented with 
human recombinant EGF and human recombinant basic FGF (Peprotech, AF-100-15 
and 100-18B), 20 ng/ml each, and 2% B27 (Invitrogen, 17504); 50% of the medium 
was substituted twice weekly.  
Bisulfite treatment and methylation-specific (MS) clone sequencing, and DNA 
methylation profiling 
DNA isolated from frozen tissues or cells was treated with bi-sulfite, and methylation 
profiling was performed using Infinium HumanMethylation 450k BeadChip 
(Illumina). MS clone sequencing was performed as previously described (Sciuscio et 
al., 2011). See also Extended Experimental Procedures. 
RNA-Seq of glioma sphere transcriptomes and data analysis 
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Total RNA isolated from GS cells was depleted from ribosomal RNA and sequencing 
libraries were prepared using TruSeq Stranded Total RNA with Ribo-Zero Gold 
(Epicentre, Illumina), followed by paired-end sequencing on Illumina Hiseq (PE 2x50 
bp; NXTGNT, University of Gent, Belgium). Details on read-alignment, 
transcriptome reconstruction and data visualization can be found in the Extended 
Experimental Procedures. 
Chromatin Immunoprecipitation followed by quantitative PCR (ChIP-qPCR) 
Chromatin was prepared using the MAGnify Chromatin Immunoprecipitation System 
(Invitrogen), precipitated with antibodies targeting the interrogated histone marks, and 
DNA quantified using qPCR as previously described [42]. See Extended 
Experimental Procedures for details on the procedure and antibodies used for 
immuno-precipitation.  
aCGH dataset 
For the NCH_EORTC samples, the Bacterial Artificial Chromosome (BAC) aCGH 
data was acquired by UCSF Humarray 2.0 and 3.0 platforms containing 2428 BACs, 
each spotted in triplicate, distributed over the human genome with an average 
resolution of 1.4Mb (http://cancer.ucsf.edu/array/index.php) [18]. Details on data 
processing and analysis are presented in the Extended Experimental Procedures.  
Selection of TCGA samples included in the analysis and data processing 
We applied two criteria to select samples from TCGA for our validation data set: 
First, the gene expression platform should have sufficient coverage of the HOX-
signature in terms of probes measuring expression levels of all 21 genes. Second, 
DNA methylation should be measured with the Illumina Infinium 450k platform, as 
this provided us a common dimension necessary to assess the similarity between the 
two datasets.  Details on the sample selection are presented in the Extended 
Experimental Procedures.  
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Data Analysis 
Unless otherwise stated, all data processing, analysis and visualization were 
performed in R version 3.1.0. Packages for specific data types and tasks are listed in 
the relevant sections. [44] 
Processing and normalization of Illumina Infinium 450k DNA methylation data 
The methylation array data of samples was loaded into R and processed using the 
BioConductor package “minfi”. The p-detection values, probabilities that the target 
sequence signal was distinguishable from the background, was used to exclude probes 
with poor quality. The probes that are unsuccessfully measured (p-detection > 0.01) in 
more than 1% of samples were dropped of the dataset. The DNA methylation 
information from the 450K BeadChip were preprocessed as in Genome Studio 
(software provided by Illumina) and they were summarized by M-values as 
recommended by Du et al. [45]. 
Processing and normalization of Affymetrix gene expression data 
The expression intensities for all probe sets from Affymetrix CEL-files were 
estimated using robust multiarray average (RMA) with probe-level quantile 
normalization and the Normalized Unscaled Standard Errors values (NUSE) were 
used to assess the relative quality of arrays. The R packages affy and affyPLM from 
BioConductor (http://www.bioconductor.org/) were used to establish normalisation 
and NUSE value. 
Normalization of Agilent gene expression data 
Level 1 Agilent gene expression data was downloaded from the TCGA for 106 
samples for which Infinium 450k DNA methylation data was available. The 
intensities within array were normalized using Loess normalization, followed by 
quantile normalization between arrays. Missing values were imputed using nearest 
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neighbor averaging method. In a last step, average intensities were calculated for 
probes, which are present more than once.  
HOX classification of samples 
We used the scaled and centered gene expression data for the 22 and 53 probes 
measuring levels of HOX-signature genes in the NCH_EORTC and TCGA samples, 
respectively. These data were used as input for an iterative kmeans clustering 
procedures. Parameters were chosen to search for the most stable cluster consisting of 
2 to 8 groups of samples, and 10000 iterations were performed. The number of groups 
was selected based on which number of clusters had the maximum Calinksi- Harabasz 
criterion value [46], thus representing the most stable partitioning of samples into 
groups/clusters. The mean HOX-signature expression levels were then calculated for 
the different groups and “high” and “low” classes were assigned based on the 
observed mean population-wide expression levels (means of the HOX-high/low 
sample means). 
Selection of Illumina Infinium 450k probes 
Probes measuring DNA methylation of the promoters of 21 HOX signature genes 
were selected based on their annotated location, resulting in a list of 400 probes. To 
reduce the dimensionality of the DNA methylation data, principle component analysis 
was performed and only the 100 probes with the highest cumulative contribution 
retained. Further details on the procedure are presented in the Extended Experimental 
Procedures. 
Correlation between Gene Copy Number and Expression 
Expression data and aCGH profiling were available for 64 GBM samples of the 
NCH_EORTC cohort. For each of those samples, the median aCGH value and the 
median gene expression value (after each gene was mean centered and divided by the 
standard deviation of its expression across those samples) were calculated for each of 
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the 39 autosomal chromosome arms. Pearson correlation coefficients between the 
median aCGH values and median expression values of all chromosomal arms were 
calculated per sample as described [17]. 
Correlation between DNA methylation and expression 
Pearson cross-correlation matrices were computed separately to investigate 
relationship between the filtered methylation data and HOX expression signature data 
sets for both NCH_EORTC and TCGA samples. A description of the detailed 
statistical procedure can be found in the Extended Experimental Procedures. 
Correlation of TCGA GBM Agilent gene and microRNA expression data 
The correlation between mean HOX-signature gene expression levels and microRNA 
expression levels were calculated using Spearman’s rho statistic to estimate rank-
based measure of association, for 96 of the 106 TCGA GBM samples. The top 2 
percentile positively and negatively correlated microRNAs were selected for further 
inspection. 
Additive effect of CNA and DNA methylation on mean HOX-signature 
expression levels 
Mean HOX-signature expression level of each sample was calculated from the scaled 
and centered expression values of each probe (22 for NCH_EORTC, 53 for TCGA). 
This value was then designated as the response variable of the linear model. The DNA 
methylation levels of the probe [M-values] were used as the first explanatory variable, 
and as a second term the CNA levels as determined by circular binary segmentation at 
cytoband chr7p15.2 were added (log2 fold change of tumor over diploid reference): 
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Figures 
Figure 1 – Cross-correlation of HOX-signature gene expression and DNA 
methylation of top 100 associated CpGs.  
(A) The heatmap visualizes the correlation between top 100 450k probes measuring 
DNA methylation of CpGs located in CpG islands of the HOXD, PROMININ1, 
HOXA, and HOXC loci (x-axis, see Table S1 for detailed probe information) and the 
expression of 21 HOX-signature genes measured by 22 Affymetrix HG-133Plus2.0 
probes (y-axis) in the NCH_EORTC GBM cohort. The probes on both axes are 
ordered according to chromosomal location. The chromosomal locations of the HOX-
signature genes are color-coded. (B) Mean correlation between each selected CpG and 
expression of the HOX-signature genes of the NCH_EORTC dataset in A. The plot in 
(C) displays the mean correlation of the validation set comprising 106 GBM samples 
from TCGA using the same set of Infinium 450k probes and a total of 53 Agilent 
probes measuring expression of HOX-signature genes (see Figure S3 for the 
corresponding heatmap). Circles highlight probes, which showed a statistically 
significant mean correlation between DNA methylation at measured CpGs probe and 
the probes measuring expression of HOX-signature genes (qvalues, FDR <=0.1). See 
also Table S2 for list of Illumina Infinium 450k probes. 
 
Figure 2 - Correlation of gene expression and gene dosage across the GBM 
genome. 
Overall expression and aCGH in 64 GBM samples of the NCH-EORTC cohort are 
shown in fine resolution. (A) Gene expression is plotted relative to non-tumoral brain 
samples. Values were smoothened and interpolated. Every row is a probeset, and 
probesets are sorted by their genomic order. (B) aCGH data. Every row is a marker, 
and markers are sorted by their genomic order. In both A and B, the samples 
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(columns) are sorted according to standard deviation in B. (C) For a single sample, 
the expression and aCGH values are shown. (D) For the same sample as in (C), the 
median of all markers on every chromosome arm is plotted against the median 
relative expression of all probesets on the same chromosomal arm. Only chromosome 
arms for which there are probesets and aCGH markers are shown. 
 
Figure 3 – HOX-signature expression levels are partially explained by DNA 
methylation and chr7p15.2 CNA 
The linear model in (A) visualises the relationship between DNA methylation of the 
probe cg05092861 (M-values) and CNA at the cytoband chr7p15.2 (log2 fold-change 
(FC) over normal reference sample), and its association with mean HOX-signature 
expression levels of the 59 NCH_EORTC GBM samples. The projected plane 
represents the predicted response, and illustrates that mean HOX-signature levels are 
highest for samples, which have an increase in CNA and decrease in DNA 
methylation. As additional information, the Copy Number status calls (based on 
segmented information from BAC CGH data) of all samples are illustrated by circles 
(normal CHR7) and triangles (CHR7 gain). See Figures S7 and S8 for the HOX 
signature based classification of samples into HOX-high and –low. Analogue to the 
model used for the NCH_EORTC data, (B) illustrates the linear model for the 103 
TCGA GBM showing the combinatorial effect of CNA increase and DNA 
methylation decrease on the increase of mean HOX-signature expression levels. 
CHR7 copy number status of individual samples is illustrated by circles (normal) and 
triangles (gain). Figure S11 illustrates the organization of TCGA samples into HOX-
high and –low groups. 
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Figure 4 – Correlation of HOXA10 expression and DNA methylation at the 
canonical and alternative promoter in 59 NCH_EORTC samples, stratified by 
CHR7 status. 
The genomic organization of the HOXA10 region on CHR7 is illustrated in (A) based 
on RefSeq annotation, retrieved from Ensembl using reference genome 
hg19/GRCh37. In addition the location of Infinium 450k probes are shown by grey 
bars at the bottom of the panel. Red bars highlight the location of the CpGs used for 
the plots in (B) and (C). In (B) four X/Y plots show the correlation between DNA 
methylation of two CpGs located in the canonical HOXA10 promoter (Region 1) and 
expression of the Affymetrix probe 214651_s_at. The top row of panels (B) and (C) 
show the expression and DNA methylation of samples with gain of CHR7 (N = 38). 
Bottom row of panels (B) and (C) show the corresponding data from samples with 
normal CHR7 status (N = 21). The CHR7 status was given by normal mixture model 
based on the weighted mean of the segmented copy number. Pearson’s product 
moment correlation coefficient (cor) and p-values are shown above each plot. Black 
lines in the plots show the fit of linear regression, in green local regression using 
lowess smoothing is shown. Figure S10 in Additional File 1 shows the correlation 
between gene expression and DNA methylation for 103 TCGA samples. 
 
Figure 5 – RNA-Seq of four glioma sphere lines and one human brain sample. 
Read densities at base pair resolution are shown across a ~120kB region of CHR7 
covering the human HOXA locus. Density of transcripts are presented separately for 
the minus (black) and plus (grey) strand and are shown as rpm/bp. The RefSeq 
annotations of the HOXA genes are shown as visual reference below the histograms. 
The location and structure of the putative HOXA9/10 read-through transcript is 
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indicated in the RefSeq annotation track as a red gene model. See Figure S12 for a 
Sashimi plot of RNA-Seq reads which support the presence of the read-through 
transcript. Locations of CpG islands (UCSC) are indicated by green bars. The grey 
boxes labelled A/B/D/E show the locations of amplicons used for ChIP-qPCR and 
methylation-specific clone sequencing (results shown in Figure 6). 
 
Figure 6 – Epigenetic features of the HOXA10 and HOXA9 promoters. 
ChIP-qPCR is shown for four different histone marks, two associated with active 
transcription/open chromatin (H3K4me3, H3K36me3) and two indicative of 
transcriptional repression (H3K27me3, H3K9me3), in our four glioma sphere lines at 
the HOXA10 promoter (A) and the HOXA9 promoter (B). The measurements 
represent relative enrichment over IgG control (error bars represent SEM in duplicate 
experiments). Methylation-specific clone sequencing is shown for the CpGi located in 
the promoter of HOXA10 in three primary GBM (C) and respective derived glioma 
sphere lines (D). The HOXA10 promoter of HOX-high GBM-2207 and GBM-2669, 
and the corresponding GS-lines (LN-2207GS, LN-2669-GS) is unmethylated, in 
contrast to the HOX-low GBM-2540 and its corresponding GS-line which exhibit 
both a highly methylated HOXA10 promoter. (E) The CpGi located in the promoter of 
HOXA9 is highly methylated in all three glioma spheres lines. Grey boxes represent 
methylated CpGs. 
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Tables 
Table 1 – Coefficients of linear models for HOX-signature expression in GBM 
datasets. 
Coefficients Estimate Std. Errora t valueb  Pr (>|t|)c R2d VIFe 
NCH_EORTC [Model 1]     0.318  
(Intercept) -0.793 0.166 -4.791 1.26e-05   
cg05092861 -0.453 0.110 -4.137 0.0001  1.001 
CNA chr7p15.2 (BAC) 1.804 0.554 3.257 0.0019   1.001 
       
NCH_EORTC [Model 2]     0.215  
(Intercept) -0.204 0.168 -1.212 0.231   
cg01078824 -0.311 0.113  -2.754 0.008  1.002 
CNA chr7p15.2 (BAC) 1.822 0.594   3.066  0.003  1.002 
       
TCGA [Model 1]     0.289  
(Intercept) -0.612 0.105 -5.822 7.07e-08    
cg05092861 -0.372 0.067 -5.542 2.44e-07  1.000 
CNA chr7p15.2 (SNP6) 0.664 0.184 3.608 0.000   1.000 
       
TCGA [Model 2]     0.254  
(Intercept) -0.158 0.088  -1.785 0.077   
cg01078824 -0.356 0.071  -4.962 2.87e-06  1.023 
CNA chr7p15.2 (SNP6) 0.799 0.191 4.186 6.13e-05  1.023 
 
Footnotes: a) standard error, b) t-statistics, c) two-sided p-values of t-statistic, d) R-
squared provides information about the variance explained by the model, and e) 
Variance inflated factor (VIF), provides information about multi-collinearity of the 
model variables. 
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Table 2 – Correlation between microRNAs and mean HOX-signature expression 
in 106 GBM samples from TCGA, top 2 percentile positively and negatively 
correlated microRNAs 
 Spearman’s rho P value (two-sided)  
hsa-miR-196b (HOXA locus) 0.69 <0.01 
hsa-miR-10b (HOXD locus) 0.50 <0.01 
hsa-miR-196a (HOXB/C locus) 0.5 <0.01 
hsa-miR-148a 0.42 <0.01 
hsa-miR-106b 0.35 <0.01 
hsa-miR-25 0.32 <0.01 
hsa-miR-496 0.31 <0.01 
hcmv-miR-UL148D 0.3 <0.01 
hsa-miR-337 0.29 <0.01 
hsa-let-7c 0.29 <0.01 
hsa-miR-130b 0.29 <0.01 
hsa-miR-199a* -0.27 <0.01 
hsa-miR-223 -0.27 <0.01 
hsa-miR-148b -0.28 <0.01 
hsa-let-7f -0.29 <0.01 
hsa-miR-125a -0.29 <0.01 
hsa-let-7d -0.3 <0.01 
hsa-miR-98 -0.3 <0.01 
hsa-let-7g -0.33 <0.01 
hsa-miR-143 -0.36 <0.01 
hsa-miR-107 -0.37 <0.01 
hsa-miR-145 -0.42 <0.01 
Lines in bold highlight microRNAs transcribed from HOX loci. 
Additional files 
Additional file 1 – Supplemental Figures, Tables (S1, S3-S10) & Extended 
Experimental Procedures  
Additional file 2 – Table S2 in XLSX format 
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